FDA will create a "Medical Innovation Development Plan" aimed at lowering health care costs by facilitating development of drugs to treat costly rare diseases through improved adaptive trial designs and statistical tools, agency chief Scott Gottlieb announced Tuesday (June 20). The Biotechnology Innovation Organization said Gottlieb's commitment to streamline clinical trials would improve outcomes and lower costs, but Public Citizen said the plan would lower the evidentiary standard for drug approvals and pose new risks to consumers. Gottlieb also said...